Journey Medical (NASDAQ:DERM) Now Covered by HC Wainwright

Key Points

• HC Wainwright has initiated coverage of Journey Medical (NASDAQ:DERM), assigning a "buy" rating and a target price of $13.00, indicating a potential upside of 74.03% from its recent close.
• Journey Medical's stock recently experienced a 5.5% increase and has a current market cap of $182.12 million, with a price-to-earnings ratio of -19.66.
• The stock has a mixed consensus rating, with three analysts rating it as a "Moderate Buy", while others have downgraded it to hold or sell ratings.

Research analysts at HC Wainwright started coverage on shares of Journey Medical (NASDAQ:DERM - Get Free Report) in a research report issued on Monday, Marketbeat.com reports. The firm set a "buy" rating and a $13.00 price target on the stock. HC Wainwright's price objective would indicate a potential upside of 80.31% from the company's current price. HC Wainwright also issued estimates for Journey Medical's Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.45) EPS, FY2026 earnings at $0.20 EPS, FY2027 earnings at $1.31 EPS, FY2028 earnings at $1.99 EPS and FY2029 earnings at $2.15 EPS.

Several other equities research analysts have also recently commented on DERM. Alliance Global Partners reissued a "buy" rating on shares of Journey Medical in a report on Thursday, May 15th. Wall Street Zen cut Journey Medical from a "buy" rating to a "hold" rating in a research report on Sunday, July 6th. Lake Street Capital boosted their price objective on Journey Medical from $9.00 to $13.00 and gave the stock a "buy" rating in a research note on Wednesday, August 13th. Finally, Zacks Research lowered Journey Medical from a "hold" rating to a "strong sell" rating in a report on Friday, August 15th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $12.17.

Journey Medical Stock Performance

Shares of NASDAQ:DERM traded down $0.06 on Monday, hitting $7.21. The company's stock had a trading volume of 132,090 shares, compared to its average volume of 197,815. The stock's 50-day moving average is $7.25 and its two-hundred day moving average is $6.68. The company has a market capitalization of $175.78 million, a price-to-earnings ratio of -18.97 and a beta of 0.80. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.95 and a current ratio of 1.27. Journey Medical has a 12 month low of $3.54 and a 12 month high of $8.90.

Journey Medical (NASDAQ:DERM - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.09). The company had revenue of $15.01 million for the quarter, compared to the consensus estimate of $14.93 million. Journey Medical had a negative return on equity of 48.69% and a negative net margin of 15.49%. On average, equities research analysts forecast that Journey Medical will post -1.02 EPS for the current year.

Institutional Trading of Journey Medical

Institutional investors have recently modified their holdings of the company. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Journey Medical in the second quarter valued at $29,000. Bank of America Corp DE lifted its holdings in shares of Journey Medical by 4,707.0% during the second quarter. Bank of America Corp DE now owns 4,134 shares of the company's stock valued at $30,000 after purchasing an additional 4,048 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Journey Medical during the second quarter valued at $36,000. JPMorgan Chase & Co. purchased a new stake in shares of Journey Medical during the second quarter valued at $41,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Journey Medical during the second quarter valued at $48,000. Institutional investors and hedge funds own 7.25% of the company's stock.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.